Approach to the Patient With Prolactinoma.
Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R.
J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-2423. doi: 10.1210/clinem/dgad174.
Antigestogens.
Baird DT.
Br Med Bull. 1993 Jan;49(1):73-87. doi: 10.1093/oxfordjournals.bmb.a072607.
Norethynodrel.
[No authors listed]
IARC Monogr Eval Carcinog Risk Chem Hum. 1979 Dec;21:461-77.
[Prolactinoma].
Glezer A, Bronstein MD.
Arq Bras Endocrinol Metabol. 2014 Mar;58(2):118-23. doi: 10.1590/0004-2730000002961.
Pituitary apoplexy: managing the life-threatening condition associated with pituitary adenomas.
Witek P.
Minerva Endocrinol. 2014 Dec;39(4):245-59. Epub 2014 Jul 29.
Multiple Endocrine Neoplasia Type 1.
Giusti F, Marini F, Brandi ML.
2005 Aug 31 [updated 2022 Mar 10]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.
Raverot G, Burman P, Abreu AP, Heaney AP, van Hulsteijn L, Lin AL, Marcus H, McCormack A, Minniti G, Petersenn S, Popovic V, Theodoropoulou M, Trouillas J, Dekkers OM.
Eur J Endocrinol. 2025 May 30;192(6):R45-R78. doi: 10.1093/ejendo/lvaf100.
[Hormonal contraception].
Van Cauwenberge JR.
Rev Med Liege. 1992 May;47(5):221-36.
Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas.
Koizumi K, Aono T.
Fertil Steril. 1986 Aug;46(2):312-4. doi: 10.1016/s0015-0282(16)49531-2.
Prolactinomas.
Katznelson L, Klibanski A.
Cancer Treat Res. 1997;89:41-55. doi: 10.1007/978-1-4615-6355-6_3.
